Journal article
Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial
AL Siebel, SK Trinh, MF Formosa, PA Mundra, AK Natoli, M Reddy-Luthmoodoo, K Huynh, AA Khan, AL Carey, G Van Hall, C Cobelli, C Dalla-Man, JD Otvos, KA Rye, J Johansson, A Gordon, NCW Wong, D Sviridov, P Barter, SJ Duffy Show all
Metabolism Clinical and Experimental | W B SAUNDERS CO-ELSEVIER INC | Published : 2016
Abstract
Aims High-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I) can modulate glucose metabolism through multiple mechanisms. This study determined the effects of a novel bromodomain and extra-terminal (BET) inhibitor (RVX-208) and putative apoA-I inducer on lipid species contained within HDL (HDL lipidome) and glucose metabolism. Materials and methods Twenty unmedicated males with prediabetes received 100 mg b.i.d. RVX-208 and placebo for 29-33 days separated by a wash-out period in a randomized, cross-over design trial. Plasma HDL-cholesterol and apoA-I were assessed as well as lipoprotein particle size and distribution using NMR spectroscopy. An oral glucose tolerance test (OGTT) proto..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This study was supported by Resverlogix Corp., the National Health & Medical Research Council (NHMRC) of Australia (APP1065462) to BAK, SJD and ALS, and in part by the Victorian Government's Operational Infrastructure Support (OIS) Program. BAK, DS and PJM are all supported by NHMRC Research Fellowships.